Antabio
2 known investors
Antabio is a clinical-stage biopharmaceutical company developing novel antibacterial treatments for drug-resistant, Gram-negative bacterial infections identified as critical priorities by the WHO and CDC, with a focus on life-threatening hospital-acquired infections. Its lead program, Meropenem-Pilabactam, is a β-lactam/β-lactamase inhibitor combination for treating multidrug-resistant infections in hospital wards and ICUs.
Investors · 2
Frequently asked questions
- What does Antabio do?
- Antabio is a clinical-stage biopharmaceutical company developing novel antibacterial treatments for drug-resistant, Gram-negative bacterial infections identified as critical priorities by the WHO and CDC, with a focus on life-threatening hospital-acquired infections. Its lead program, Meropenem-Pilabactam, is a β-lactam/β-lactamase inhibitor combination for treating multidrug-resistant infections in hospital wards and ICUs.
- Who are Antabio's investors?
- Antabio's investors include AMR Action Fund, BNP Paribas Développement.